Adalimumab is a biologic medicine used to manage moderate to severe Crohn’s disease in eligible patients. It works by blocking tumor necrosis factor alpha, a protein involved in inflammation. Understanding its uses, administration, potential side effects, and monitoring requirements helps patients learn how this treatment may support symptom control and intestinal healing under medical supervision.
Crohn’s disease is a chronic inflammatory bowel disease that can affect different parts of the digestive tract. Symptoms may include abdominal pain, diarrhea, fatigue, weight loss, and reduced appetite. Treatment aims to control inflammation, maintain remission, and reduce complications. Adalimumab is one option healthcare professionals may consider when conventional treatments do not provide adequate control or when a biologic therapy is appropriate.
Adalimumab is a biologic medication classified as a tumor necrosis factor alpha (TNF-alpha) inhibitor. TNF-alpha is a protein that contributes to inflammation in the body. By blocking its activity, adalimumab can help reduce the inflammatory response associated with Crohn’s disease.
Healthcare professionals may prescribe adalimumab to eligible adults and children, depending on age, clinical circumstances, and local regulatory approvals. Its primary purpose is to control active disease and help maintain remission.
Reducing intestinal inflammation: Adalimumab targets TNF-alpha to help decrease inflammation in the digestive tract.
Managing symptoms: Treatment may help reduce diarrhea, abdominal discomfort, and other symptoms associated with active Crohn’s disease.
Supporting remission: In appropriate patients, continued treatment can help maintain disease control and reduce the likelihood of symptom recurrence.
Promoting intestinal healing: By controlling inflammation, adalimumab may support healing of the intestinal lining and help reduce ongoing inflammatory damage.
Addressing inadequate response to other treatments: It may be considered when corticosteroids, immunomodulators, or other appropriate therapies have not worked sufficiently or are unsuitable.
The response to treatment varies between individuals. Doctors assess symptoms, laboratory results, and sometimes endoscopic or imaging findings to determine whether the medication is effective.
Adalimumab is generally administered as a subcutaneous injection, meaning it is injected under the skin. The initial dosing schedule and subsequent maintenance doses depend on the patient's age, condition, prescription, and local product information. Patients should follow the instructions provided by their healthcare professional.
Monitoring is important because adalimumab affects the immune system and may increase susceptibility to certain infections.
Infection screening: Patients are generally assessed for tuberculosis and hepatitis B before starting treatment, as these infections may become active during therapy.
Common side effects: Injection-site reactions, headaches, and upper respiratory tract infections may occur.
Serious risks: Severe infections and other significant complications are possible. Rarely, treatment may be associated with serious allergic reactions or nervous system problems.
Vaccination considerations: Live vaccines are generally avoided during treatment. Vaccination needs should be reviewed with a healthcare professional before therapy begins.
Ongoing assessment: Doctors may monitor symptoms, blood tests, infection signs, and other indicators of treatment response.
Patients should inform their healthcare team about existing infections, other medical conditions, vaccinations, and medications before starting adalimumab. They should seek prompt medical attention for symptoms such as persistent fever, difficulty breathing, or signs of a serious infection.
Adalimumab can be an effective treatment option for selected people with Crohn’s disease, but it is not suitable for everyone. Treatment decisions require an individualized assessment of disease activity, previous therapies, potential risks, and expected benefits. Regular medical follow-up helps determine whether treatment should continue or whether another management approach is needed.